查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1771707

灰指甲市场规模、份额、趋势分析报告：按类型、治疗方法、地区、细分市场预测，2025-2033

Onychomycosis Market Size, Share & Trends Analysis Report By Type (Distal Subungual Onychomycosis, White Superficial Onychomycosis, Proximal Subungual Onychomycosis), By Treatment (Oral, Topical), By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

灰指甲市场的成长与趋势：

根据Grand View Research的最新报告，全球甲癣市场规模预计到2033年将达到57.4亿美元。预计2025年至2033年期间，该市场的复合年增长率将达到4.7%。甲癣市场的成长归因于甲癣和慢性疾病发病率的上升，以及人们对治疗的认识的提高。由于感染疾病会导致心理和社会影响，限制个人的工作和社交生活，因此为感染疾病患者提供有效且高效的治疗至关重要，这进一步推动了市场的成长。

甲癣发生率的上升是推动整体市场成长的主要因素。这种感染疾病通常被称为甲癣或真菌性指甲感染疾病，影响美国超过14%的总人口。然而，儘管甲癣具有高度传染性，且患病风险会随着老龄化增长而增加，但大多数人并未意识到甲癣的危害。

全球灰指甲组织等国际组织正与世界各地的公共卫生部门和医疗保健专业人士合作，提高大众对灰指甲的认识，并改善全球的预防和治疗。这有望推动治疗药物的需求。美国疾病管制与预防中心 (CDC) 发起的「思考灰指甲」等政府倡议强调了在患者早期发现灰指甲等真菌疾病并确保适当治疗的重要性。这导致灰指甲治疗药物的需求激增，预计将推动该国市场的成长。

此外，主要参与者正致力于合作与伙伴关係关係，以开发新型甲癣治疗方法，并保持市场竞争力。例如，2022年8月，Moberg Pharma AB与Padagis Israel Agencies Ltd.签署了分销协议，授予Padagis在以色列甲癣治疗药物MOB-015的独家分销权。此外，旨在解决诸如提高患者依从性和减少剂量等问题的技术创新预计将推动市场成长。例如，Intas Pharmaceuticals于2021年10月以Itaspor-SB Forte/Subawin为品牌推出了全球首款高生物利用度ItraconazoleSB 100mg。预计此举将显着提高患者依从性并降低治疗成本。

灰指甲市场报告重点

  • 预计远端甲下甲癣领域将在 2024 年占据市场主导地位，这得益于 FDA 批准的非专利核准数量的增加和普及度的提高，以满足日益增长的需求。
  • 由于使用和管理方便，外用药物部分预计将在预测期内以最快的速度增长，从而提高患者的治疗依从性。
  • 竞争对手正专注于获取资本密集的专业能力，以加强和维持其竞争地位。
  • 2024 年，北美占据了最大的市场占有率，这得益于其良好的医疗保健条件、广泛的目标人口以及高渗透率的治疗。

目录

第一章调查方法与范围

第二章执行摘要

第三章 灰指甲市场变数、趋势与范围

  • 市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 商业环境分析
    • 产业分析-波特五力分析
    • PESTLE分析
    • 管道分析
    • 专利到期分析
    • 定价分析

第四章 灰指甲市场：按类型分類的业务分析

  • 2025 年及 2033 年各类型市场占有率
  • 类型细分仪表板
  • 按类型分類的市场规模、预测和趋势分析（2021-2033 年）
  • 远端甲下甲癣
  • 白色浅层甲癣
  • 近端甲下甲癣
  • 其他类型

第五章 灰指甲市场：依治疗的业务分析

  • 2025年和2033年的治疗市场占有率
  • 治疗细分仪表板
  • 市场规模、预测与趋势分析（治疗，2021-2033 年）
  • 口服
  • 局部的
  • 其他的

第六章 灰指甲市场：区域评估与趋势分析

  • 2025年及2033年区域市场占有率分析
  • 区域市场仪表板
  • 2021-2033年市场规模与预测趋势分析：
  • 北美洲
    • 按国家/地区，2021-2033 年
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第七章 竞争态势

  • 参与者概览
  • 企业市场分析
  • 公司分类
  • 战略地图
  • 公司简介/上市公司
    • Bausch Health Companies Inc.
    • GSK plc
    • Abbott
    • Pfizer Inc
    • Bayer AG
    • Teva Pharmaceutical Industries Ltd.
    • Cipla
    • Merck &Co., Inc.
    • Novartis AG
    • Sun Pharmaceutical Industries Ltd.
Product Code: GVR-4-68040-031-4

Onychomycosis Market Growth & Trends:

The global onychomycosis market size is anticipated to reach USD 5.74 billion by 2033, according to a new report by Grand View Research, Inc. The market is projected to grow at a CAGR of 4.7% from 2025 to 2033. The growth of the onychomycosis market is attributable to the increasing incidence of onychomycosis and chronic diseases aided by rising awareness about treatment. The infection leads to psychological and social limitations which can limit an individual's ability to work and socialize which makes it important to provide effective and efficient treatment for patients suffering from the infection further propelling the market growth.

Rising rate of onychomycosis is the key factor contributing to the overall growth of the market. The infection, often known as toenail fungus or fungal nail infection, affects over 14% of the total population in the U.S. However, most people are unaware of how harmful toenail fungus is, despite it is extremely contagious in nature and increasing the risk of developing with age.

International organizations such as the Global Nail Fungus Organization are working with public health officials and healthcare professionals worldwide to increase awareness and improve the prevention and treatment of nail fungus across the globe. This is anticipated to propel the demand for therapeutics. Government initiatives such as Think Fungus by the Centers for Disease Control and Prevention (CDC), emphasize the significance of detecting fungal diseases such as onychomycosis, early enough in the course of a patient's condition to ensure the administration of relevant therapy. This is inducing a surge in demand for onychomycosis therapeutics and is expected to drive market growth in the country.

Furthermore, the key players are focusing on collaborations and partnerships to develop novel onychomycosis therapies and to maintain their competitive position in the market. For instance, in August 2022, Moberg Pharma AB entered into a distribution agreement with Padagis Israel Agencies Ltd. that is expected to give Padagis exclusive rights for selling and marketing MOB-015, a treatment for onychomycosis in Israel. Moreover, innovations to address the concerns such as improving patient compliance and reducing the dosage are expected to fuel the market growth. For instance, in October 2021, Intas Pharmaceuticals launched SB 100mg under the brand name Itaspor-SB Forte/Subawin which is the world's first Super Bioavailable Itraconazole. This initiative is expected to significantly increase patient compliance and reduce the cost of therapy.

Onychomycosis Market Report Highlights:

  • Distal subungual onychomycosis segment dominated the market in 2024 and is attributable to the increasing prevalence and number of generic approvals by the FDA to meet the rising demands
  • Topical segment is expected to show the fastest growth rate over the forecast period owing to ease of usage and administration which leads to increased patient compliance with treatment
  • Players have an increased focus on acquiring specialized capacities that are highly capital-intensive to develop and maintain their competitive position
  • North America held the largest market share in 2024 which can be attributed to better access to healthcare, the presence of a wide target population, and high adoption of treatment

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Treatment
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Onychomycosis Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. Onychomycosis Market: Type Business Analysis

  • 4.1. Type Market Share, 2025 & 2033
  • 4.2. Type Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Type, 2021 to 2033 (USD Million)
  • 4.4. Distal Subungual Onychomycosis
    • 4.4.1. Distal Subungual Onychomycosis Market, 2021 - 2033 (USD Million)
  • 4.5. White Superficial Onychomycosis
    • 4.5.1. White Superficial Onychomycosis Market, 2021 - 2033 (USD Million)
  • 4.6. Proximal Subungual Onychomycosis
    • 4.6.1. Proximal Subungual Onychomycosis Market, 2021 - 2033 (USD Million)
  • 4.7. Other Types
    • 4.7.1. Other Types Market, 2021 - 2033 (USD Million)

Chapter 5. Onychomycosis Market: Treatment Business Analysis

  • 5.1. Treatment Market Share, 2025 & 2033
  • 5.2. Treatment Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Treatment, 2021 to 2033 (USD Million)
  • 5.4. Oral
    • 5.4.1. Oral Market, 2021 - 2033 (USD Million)
  • 5.5. Topical
    • 5.5.1. Topical Market, 2021 - 2033 (USD Million)
  • 5.6. Others
    • 5.6.1. Others Market, 2021 - 2033 (USD Million)

Chapter 6. Onychomycosis Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2025 & 2033
  • 6.2. Regional Market Dashboard
  • 6.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 6.4. North America
    • 6.4.1. North America Onychomycosis Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
    • 6.4.2. U.S.
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Target Disease Prevalence
      • 6.4.2.3. Regulatory Framework
      • 6.4.2.4. Reimbursement Framework
      • 6.4.2.5. U.S. Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.3. Canada
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Target Disease Prevalence
      • 6.4.3.3. Regulatory Framework
      • 6.4.3.4. Reimbursement Framework
      • 6.4.3.5. U.S. Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.4. Mexico
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Target Disease Prevalence
      • 6.4.4.3. Regulatory Framework
      • 6.4.4.4. Reimbursement Framework
      • 6.4.4.5. Mexico Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Europe
    • 6.5.1. Europe Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.2. UK
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Target Disease Prevalence
      • 6.5.2.3. Regulatory Framework
      • 6.5.2.4. Reimbursement Framework
      • 6.5.2.5. Uk Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.3. Germany
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Target Disease Prevalence
      • 6.5.3.3. Regulatory Framework
      • 6.5.3.4. Reimbursement Framework
      • 6.5.3.5. Germany Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.4. France
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Target Disease Prevalence
      • 6.5.4.3. Regulatory Framework
      • 6.5.4.4. Reimbursement Framework
      • 6.5.4.5. France Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.5. Italy
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Target Disease Prevalence
      • 6.5.5.3. Regulatory Framework
      • 6.5.5.4. Reimbursement Framework
      • 6.5.5.5. Italy Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.6. Spain
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Target Disease Prevalence
      • 6.5.6.3. Regulatory Framework
      • 6.5.6.4. Reimbursement Framework
      • 6.5.6.5. Spain Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.7. Denmark
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Target Disease Prevalence
      • 6.5.7.3. Regulatory Framework
      • 6.5.7.4. Reimbursement Framework
      • 6.5.7.5. Denmark Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.8. Sweden
      • 6.5.8.1. Key Country Dynamics
      • 6.5.8.2. Target Disease Prevalence
      • 6.5.8.3. Regulatory Framework
      • 6.5.8.4. Reimbursement Framework
      • 6.5.8.5. Sweden Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.9. Norway
      • 6.5.9.1. Key Country Dynamics
      • 6.5.9.2. Target Disease Prevalence
      • 6.5.9.3. Regulatory Framework
      • 6.5.9.4. Reimbursement Framework
      • 6.5.9.5. Norway Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.2. Japan
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Target Disease Prevalence
      • 6.6.2.3. Regulatory Framework
      • 6.6.2.4. Reimbursement Framework
      • 6.6.2.5. Japan Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.3. China
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Target Disease Prevalence
      • 6.6.3.3. Regulatory Framework
      • 6.6.3.4. Reimbursement Framework
      • 6.6.3.5. China Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.4. India
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Target Disease Prevalence
      • 6.6.4.3. Regulatory Framework
      • 6.6.4.4. Reimbursement Framework
      • 6.6.4.5. India Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.5. Australia
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Target Disease Prevalence
      • 6.6.5.3. Regulatory Framework
      • 6.6.5.4. Reimbursement Framework
      • 6.6.5.5. Australia Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.6. South Korea
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Target Disease Prevalence
      • 6.6.6.3. Regulatory Framework
      • 6.6.6.4. Reimbursement Framework
      • 6.6.6.5. South Korea Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.7. Thailand
      • 6.6.7.1. Key Country Dynamics
      • 6.6.7.2. Target Disease Prevalence
      • 6.6.7.3. Regulatory Framework
      • 6.6.7.4. Reimbursement Framework
      • 6.6.7.5. Thailand Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Target Disease Prevalence
      • 6.7.2.3. Regulatory Framework
      • 6.7.2.4. Reimbursement Framework
      • 6.7.2.5. Japan Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Target Disease Prevalence
      • 6.7.3.3. Regulatory Framework
      • 6.7.3.4. Reimbursement Framework
      • 6.7.3.5. China Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8. Middle East and Africa
    • 6.8.1. Middle East and Africa Onychomycosis Market Estimates and Forecasts, 2017 - 2033 (USD Million)
    • 6.8.2. South Africa
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Target Disease Prevalence
      • 6.8.2.3. Regulatory Framework
      • 6.8.2.4. Reimbursement Framework
      • 6.8.2.5. South Africa Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Key Country Dynamics
      • 6.8.3.2. Target Disease Prevalence
      • 6.8.3.3. Regulatory Framework
      • 6.8.3.4. Reimbursement Framework
      • 6.8.3.5. Saudi Arabia Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.4. UAE
      • 6.8.4.1. Key Country Dynamics
      • 6.8.4.2. Target Disease Prevalence
      • 6.8.4.3. Regulatory Framework
      • 6.8.4.4. Reimbursement Framework
      • 6.8.4.5. UAE Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.5. Kuwait
      • 6.8.5.1. Key Country Dynamics
      • 6.8.5.2. Target Disease Prevalence
      • 6.8.5.3. Regulatory Framework
      • 6.8.5.4. Reimbursement Framework
      • 6.8.5.5. Kuwait Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. Bausch Health Companies Inc.
      • 7.5.1.1. Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Product Benchmarking
      • 7.5.1.4. Strategic Initiatives
    • 7.5.2. GSK plc
      • 7.5.2.1. Overview
      • 7.5.2.2. Financial Performance
      • 7.5.2.3. Product Benchmarking
      • 7.5.2.4. Strategic Initiatives
    • 7.5.3. Abbott
      • 7.5.3.1. Overview
      • 7.5.3.2. Financial Performance
      • 7.5.3.3. Product Benchmarking
      • 7.5.3.4. Strategic Initiatives
    • 7.5.4. Pfizer Inc
      • 7.5.4.1. Overview
      • 7.5.4.2. Financial Performance
      • 7.5.4.3. Product Benchmarking
      • 7.5.4.4. Strategic Initiatives
    • 7.5.5. Bayer AG
      • 7.5.5.1. Overview
      • 7.5.5.2. Financial Performance
      • 7.5.5.3. Product Benchmarking
      • 7.5.5.4. Strategic Initiatives
    • 7.5.6. Teva Pharmaceutical Industries Ltd.
      • 7.5.6.1. Overview
      • 7.5.6.2. Financial Performance
      • 7.5.6.3. Product Benchmarking
      • 7.5.6.4. Strategic Initiatives
    • 7.5.7. Cipla
      • 7.5.7.1. Overview
      • 7.5.7.2. Financial Performance
      • 7.5.7.3. Product Benchmarking
      • 7.5.7.4. Strategic Initiatives
    • 7.5.8. Merck & Co., Inc.
      • 7.5.8.1. Overview
      • 7.5.8.2. Financial Performance
      • 7.5.8.3. Product Benchmarking
      • 7.5.8.4. Strategic Initiatives
    • 7.5.9. Novartis AG
      • 7.5.9.1. Overview
      • 7.5.9.2. Financial Performance
      • 7.5.9.3. Product Benchmarking
      • 7.5.9.4. Strategic Initiatives
    • 7.5.10. Sun Pharmaceutical Industries Ltd.
      • 7.5.10.1. Overview
      • 7.5.10.2. Financial Performance
      • 7.5.10.3. Product Benchmarking
      • 7.5.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global onychomycosis market, by region, 2021 - 2033 (USD Million)
  • Table 4 Global onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 5 Global onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 6 North America onychomycosis market, by country, 2021 - 2033 (USD Million)
  • Table 7 North America onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 8 North America onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 9 U.S. onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 10 U.S. onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 11 Canada onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 12 Canada onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 13 Mexico onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 14 Mexico onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 15 Europe onychomycosis market, by country, 2021 - 2033 (USD Million)
  • Table 16 Europe onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 17 Europe onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 18 UK onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 19 UK onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 20 Germany onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 21 Germany onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 22 France onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 23 France onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 24 Italy onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 25 Italy onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 26 Spain onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 27 Spain onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 28 Norway onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 29 Norway onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 30 Denmark onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 31 Denmark onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 32 Sweden onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 33 Sweden onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 34 Asia Pacific onychomycosis market, by country, 2021 - 2033 (USD Million)
  • Table 35 Asia Pacific onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 36 Asia Pacific onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 37 Japan onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 38 Japan onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 39 China onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 40 China onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 41 India onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 42 India onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 43 Australia onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 44 Australia onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 45 South Korea onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 46 South Korea onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 47 Thailand onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 48 Thailand onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 49 Latin America onychomycosis market, by country, 2021 - 2033 (USD Million)
  • Table 50 Latin America onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 51 Latin America onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 52 Brazil onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 53 Brazil onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 54 Argentina onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 55 Argentina onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 56 Middle East & Africa Onychomycosis market, by country, 2021 - 2033 (USD Million)
  • Table 57 Middle East & Africa onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 58 Middle East & Africa onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 59 South Africa onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 60 South Africa onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 61 Saudi Arabia onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 62 Saudi Arabia onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 63 UAE onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 64 UAE onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 65 Kuwait onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 66 Kuwait onychomycosis market, by treatment, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Onychomycosis market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Therapeutic approach and application outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Onychomycosis market dynamics
  • Fig. 12 Onychomycosis market: Porter's five forces analysis
  • Fig. 13 Onychomycosis market: PESTLE analysis
  • Fig. 14 Product market, 2021 - 2033 (USD Million)
  • Fig. 15 Distal Subungual Onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 16 White Superficial Onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 17 Proximal Subungual Onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 18 Other Types market, 2021 - 2033 (USD Million)
  • Fig. 19 Treatment market, 2021 - 2033 (USD Million)
  • Fig. 20 Oral market, 2021 - 2033 (USD Million)
  • Fig. 21 Topical market, 2021 - 2033 (USD Million)
  • Fig. 22 Others market, 2021 - 2033 (USD Million)
  • Fig. 23 Onychomycosis market revenue, by region
  • Fig. 24 Regional marketplace: Key takeaways
  • Fig. 25 North America onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 26 U.S. country dynamics
  • Fig. 27 U.S. onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 28 Canada country dynamics
  • Fig. 29 Canada onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 30 Mexico country dynamics
  • Fig. 31 Mexico onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 32 Europe onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 33 UK country dynamics
  • Fig. 34 UK onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 35 Germany country dynamics
  • Fig. 36 Germany onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 37 France country dynamics
  • Fig. 38 France onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 39 Italy country dynamics
  • Fig. 40 Italy onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 41 Spain country dynamics
  • Fig. 42 Spain onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 43 Norway country dynamics
  • Fig. 44 Norway onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 45 Sweden country dynamics
  • Fig. 46 Sweden onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 47 Denmark country dynamics
  • Fig. 48 Denmark onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 49 Asia Pacific onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 50 Japan country dynamics
  • Fig. 51 Japan onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 52 China country dynamics
  • Fig. 53 China onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 54 India country dynamics
  • Fig. 55 India onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 56 Australia country dynamics
  • Fig. 57 Australia onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 58 South Korea country dynamics
  • Fig. 59 South Korea onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 60 Thailand country dynamics
  • Fig. 61 Thailand onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 62 Latin America onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 63 Brazil country dynamics
  • Fig. 64 Brazil onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 65 Argentina country dynamics
  • Fig. 66 Argentina onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 67 MEA onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 68 South Africa country dynamics
  • Fig. 69 South Africa onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 70 Saudi Arabia country dynamics
  • Fig. 71 Saudi Arabia onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 72 UAE country dynamics
  • Fig. 73 UAE onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 74 Kuwait country dynamics
  • Fig. 75 Kuwait onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 76 Company categorization
  • Fig. 77 Company market position analysis
  • Fig. 78 Strategic framework